sulfamethoxazole brands

78 registered brands containing sulfamethoxazole in Malawi.

sulfamethoxazole

PubChem CID 5329

Molecular formula: C10H11N3O3S

Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydrofolic acid synthesis due to its structural similarity to an endogenous substrate, para-aminobenzoic acid (PABA). Most bacteria meet their need for folic acid by synthesizing it from PABA, as opposed to Animalia that require exogenous folic acid sources. Sulfamethoxazole competitively inhibits dihydropteroate synthase, the enzyme responsible for bacterial conversion of PABA to dihydrofolic acid. Inhibition of this pathway prevents the synthesis of tetrahydrofolate and, ultimately, the synthesis of bacterial purines and DNA, resulting in a bacteriostatic effect. Sulfonamides are usually bacteriostatic in action. Sulfonamides interfere with the utilization of p-aminobenzoic acid (PABA) in the biosynthesis of tetrahydrofolic acid (the reduced form of folic acid) cofactors in susceptible bacteria. Sulfonamides are structural analogs of PABA and appear to interfere with PABA utilization by competitively inhibiting the enzyme dihydropteroate synthase, which catalyzes the formation of dihydropteroic acid (a precursor of tetrahydrofolic acid) from PABA and pteridine; however, other mechanism(s) affecting the biosynthetic pathway also may be involved. Compounds such as pyrimethamine and trimethoprim, which block later stages in the synthesis of folic acid, act synergistically with sulfonamides. Only microorganisms that synthesize their own folic acid are inhibited by sulfonamides; animal cells and bacteria which are capable of utilizing folic acid precursors or preformed folic acid are not affected by these drugs. The antibacterial activity of the sulfonamides is reportedly decreased in the presence of blood or purulent body exudates. /Sulfonamides/ /Sulfonamides inhibit bacterial growth by preventing para-aminobenzoic acid (PABA) from being incorporated/ into dihydropteroic acid, the immediate precursor of folic acid. Sensitive microorganisms are those that must synthesize their own folic acid; bacteria that can utilize preformed folate are not affected. Bacteriostasis induced by sulfonamides is counteracted by PABA competitively. Sulfonamides do not affect mammalian cells by this mechanism, since they require preformed folic acid and cannot synthesize it. /Sulfonamides/ Sulfonamides are broad-spectrum, bacteriostatic anti-infectives. They are structural analogs of para-aminobenzoic acid and competively inhibit a bacterial enzyme, dihydropteroate synthetase, that is responsible for incorporation of para-aminobenzoic acid into dihydrofolic acid. This blocks the synthesis of dihydrofolic acid and decreases the amount of metabolically active tetrahydrofolic acid, a cofactor for the synthesis of purines, thymidine, and DNA. /Sulfonamides/ The hydroxylamine and nitroso metabolites formed by N4-oxidation of sulfonamides are thought to be involved in the pathogenesis of idiosyncratic reactions to this class of drugs. Idiosyncratic reactions to sulfonamides are characterized by multisystemic toxicity, including hepatitis, nephritis, dermatitis, and blood dyscrasias (aplastic anemia, agranulocytosis). Previously it has been shown that cytochrome p-450 in the liver metabolizes sulfamethoxazole to its hydroxylamine metabolite. In this paper the N4-oxidation of sulfamethoxazole by activated monocytes and neutrophils (human and canine) to form sulfamethoxazole hydroxylamine and nitrosulfamethoxazole is reported. The presumed nitroso intermediate was not detected. Purified myeloperoxidase and prostaglandin H synthase were also capable of mediating the oxidation of sulfamethoxazole. The present studies suggest that myeloperoxidase is responsible for the observed oxidation by phagocytic cells. Oxidation by neutrophils may play a role in agranulocytosis, and oxidation by monocytes may facilitate antigen presentation. Extrahepatic bioactivation of sulfonamides by peroxidases in phagocytic cells and other tissues may be important in determining the range of adverse reactions to sulfonamides

Source: PubChem (NCBI) ยท compound 5329

Product Manufacturer Status Country
ALPRIM 480MG TABLET
TABLET
- Registered Malawi
ASTRIM 480MG TABLET
TABLET
- Registered Malawi
ASTRIM 960 960MG TABLET
TABLET
- Registered Malawi
BETRIM-480 480MG TABLET
TABLET
- Registered Malawi
BISEPTON 240MG/5ML ORAL 240MG/5ML ORAL SUSPENSION
ORAL SUSPENSION
- Registered Malawi
BISEPTON 480MG 480MG TABLET
TABLET
- Registered Malawi
BRAVATRIM 480MG TABLET
TABLET
- Registered Malawi
CADIPRIM 240MG/5ML SUSPENSION
SUSPENSION
- Registered Malawi
CIPLIN 240MG/100ML SUSPENSION
SUSPENSION
- Registered Malawi
CIPLIN 480MG TABLET
TABLET
- Registered Malawi
CIPLIN COMBINATION PRODUCT TABLET
TABLET
- Registered Malawi
CIPLIN-DS 800MG/160MG TABLET
TABLET
- Registered Malawi
CIPLIN>DS 960MG TABLET
TABLET
- Registered Malawi
CIPLIN DS 960MG TABLET
TABLET
- Registered Malawi
CO-TRIMOXAZOLE 240MG/5ML SUSPENSION
SUSPENSION
- Registered Malawi
CO-TRIMOXAZOLE 480MG TABLET
TABLET
- Registered Malawi
CO-TRIMOXAZOLE 480MG TABLET
TABLET
- Registered Malawi
CO-TRIMOXAZOLE 480MG TABLET
TABLET
- Registered Malawi
CO-TRIMOXAZOLE 960MG TABLET
TABLET
- Registered Malawi
CO-TRIMOXAZOLE 960 960MG TABLET
TABLET
- Registered Malawi
COMAX 240MG/5ML SUSPENSION
SUSPENSION
- Registered Malawi
COMAX 480MG TABLET
TABLET
- Registered Malawi
COMBACT 240 MG/ 5 ML SUSPENSION
SUSPENSION
- Registered Malawi
COMBACT 480 MG TABLET
TABLET
- Registered Malawi
COTRIKANT 240MG/5ML SUSPENSION
SUSPENSION
- Registered Malawi
COTRIKANT 480MG TABLET
TABLET
- Registered Malawi
COTRIKANT 960 960MG TABLET
TABLET
- Registered Malawi
COTRIM-480 480MG TABLET
TABLET
- Registered Malawi
COTRIM SUSPENSION 240MG SUSPENSION
SUSPENSION
- Registered Malawi
COTRIMOL 480MG TABLET
TABLET
- Registered Malawi
COTRIMOL 480 480MG TABLET
TABLET
- Registered Malawi
COTRIMOL 960 960MG TABLET
TABLET
- Registered Malawi
COTRIMOXAZOLE 240MG/5ML POWDER FOR SUSPENSION
POWDER FOR SUSPENSION
- Registered Malawi
COTRIMOXAZOLE 480MG TABLET
TABLET
- Registered Malawi
COTRIMOXAZOLE 480MG TABLET
TABLET
- Registered Malawi
COTRIMOXAZOLE COMBINATION PRODUCT TABLET
TABLET
- Registered Malawi
COTRIMOXAZOLE. COMBINATION PRODUCT TABLET
TABLET
- Registered Malawi
COTRIZOLE 240MG/5ML SUSPENSION
SUSPENSION
- Registered Malawi
COZOLE 240MG/5ML SUSPENSION
SUSPENSION
- Registered Malawi
DEPRIM 480MG TABLET
TABLET
- Registered Malawi
EMTRIM 480MG TABLET
TABLET
- Registered Malawi
EMTRIM FORTE 960MG TABLET
TABLET
- Registered Malawi
FAMETRIM-480 480MG TABLETS
TABLETS
- Registered Malawi
FARCOTRIM 480MG TABLET
TABLET
- Registered Malawi
ISONIAZID PYRIDOXINE SULFAMETHOXAZOLE TRIMETHOPRIM 300/25/800/160MG TABLET
TABLET
- Registered Malawi
KETACOTRIZOLE 480MG TABLET
TABLET
- Registered Malawi
L-TRIM 240MG/5ML SUSPENSION
SUSPENSION
- Registered Malawi
L-TRIM 480MG TABLET
TABLET
- Registered Malawi
LECOTRIM 240MG SUSPENSION
SUSPENSION
- Registered Malawi
LECOTRIM 480MG TABLET
TABLET
- Registered Malawi
12